|
Sernova Corp. (TSX:V-SVA) is a Canadian-based medical device and combination product development company benefiting patients with chronic metabolic, neurological, and haematological diseases with a first product focus on diabetes, partaking in the near-term $8 billion cell therapy market.
Sernova, is developing two novel closely integrated proprietary platform technologies.
The first is the Cell Pouch System™, a scalable device providing a natural "organ-like" environment for therapeutic cells such as insulin producing islets for diabetics and the second is Sertolin™, a cell-based technology providing an immune-privileged environment for donor cells, reducing or eliminating the need for anti-rejection drugs.
Using a medical device and combination product strategy Sernova partakes in the rapidly expanding cell therapy market which positions the company for significant growth and revenue upon commercialization of its "paradigm-shifting" technology.
Sernova's team is immediately focused development of the Cell Pouch System™ for treatment of insulin-dependent diabetes which could benefit both Type-1 and many Type-2 patients, currently at 9m North American patients and plans to commercialize products for Parkinson's, spinal cord injury, and haemophilia among other debilitating diseases.
Sernova holds exclusive rights to multiple patents and associated intellectual property for the therapeutic use of Sertoli cells and has filed patents on the Cell Pouch System™.
Dr. David White - Principal Researcher |
Please click on the link to listen to an interview with Sernova's Principal Scientist, Dr. White in which he discusses the primary causes and effects of diabetes as well as work being done through therapeutic cell transplantation to restore afflicted patients back to health: Audio Interview
|
| |
Jan 25, 2010: News Releases: Sernova To Present At Biopartnering North America Conference (more...)
Dec 31, 2009: News Releases: Sernova Completes $500,000 Private Placement (more...)
Nov 10, 2009: News Releases: Appointment Of Hans Mader To The Sernova Business Advisory Board (more...)
View PDF (1.55 mb) | |
